119 - The New Landscape of CMV in Transplant

Friday, October 21, 2022

10:30 AM – 11:45 AM US ET

Location: 201

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Steven Pergam, MD, MPH

Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center Associate Professor, University of Washington School of Medicine
Fred Hutchinson Cancer Center
Seattle, WA, United States

Disclosure(s): Global Life Technologies, Inc.: Grant/Research Support (Ongoing); Merck and Company, Inc.: Participated in research trial (Terminated)
Maricar Malinis, MD

Associate Professor of Medicine and Transplant (Surgery), Medical Director of Transplant and Oncology ID
Yale School of Medicine
New Haven, CT, United States

Disclosure(s): Aicuris: Primary investigator of clinical trial at Yale site, renumeration goes to institution (Ongoing); Takeda: primary investigator of clinical trial at yale site, renumeration goes to institution (Ongoing)

Faculty(s)

Camille Kotton, MD

clinical director, transplant ID
Massachusetts General Hospital
Boston, MA, United States

Disclosure(s): BeiGene: Advisor/Consultant (Terminated), Grant/Research Support (Terminated); Biotest: Advisor/Consultant (Ongoing); Exevir: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Oxford Immunotech: Advisor/Consultant (Ongoing); Takeda/Shire: Advisor/Consultant (Ongoing)

Slides
W. Justin Moore, PharmD, BCPS, BCIDP

ID Clinical Pharmacist
Pharmacy
Northwestern Medicine
Chicago, IL, United States

Disclosure(s): No financial relationships to disclose

Slides
Michelle Yong, MBBS, FRACP, MPH, PhD

Infectious Diseases Physician
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia

Disclosure(s): Merck/MSD: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Takeda: Advisor/Consultant (Terminated)

Slides

Disclosure(s):

Steven Pergam, MD, MPH: Global Life Technologies, Inc.: Grant/Research Support (Ongoing); Merck and Company, Inc.: Participated in research trial (Terminated)

Maricar F. Malinis, MD: Aicuris: Primary investigator of clinical trial at Yale site, renumeration goes to institution (Ongoing); Takeda: primary investigator of clinical trial at yale site, renumeration goes to institution (Ongoing)

Camille Kotton, MD: BeiGene: Advisor/Consultant (Terminated), Grant/Research Support (Terminated); Biotest: Advisor/Consultant (Ongoing); Exevir: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Oxford Immunotech: Advisor/Consultant (Ongoing); Takeda/Shire: Advisor/Consultant (Ongoing)

W. Justin Moore, PharmD, BCPS, BCIDP: No financial relationships to disclose

Michelle Yong, MBBS, FRACP, MPH, PhD: Merck/MSD: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Takeda: Advisor/Consultant (Terminated)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe clinical uses for Maribavir in the treatment of CMV infections in transplantation;
discuss the benefits and limitations of Letermovir prophylaxis for CMV prevention

Presentations:

10:30 AM – 10:55 AM US ET

The Newest Tool in the CMV Toolbox: How to Use Maribavir in Transplant
Speaker: Camille Kotton, MD – Massachusetts General Hospital
10:55 AM – 11:20 AM US ET

What Have We Learned From Half a Decade of Letermovir?
Speaker: W. Justin Moore, PharmD, BCPS, BCIDP – Northwestern Medicine
11:20 AM – 11:45 AM US ET

How Can We Harness New and Emerging Immune Assays to Understand Prevention and Treatment of CMV in Transplant?
Speaker: Michelle Yong, MBBS, FRACP, MPH, PhD – Peter MacCallum Cancer Centre